| Bioactivity | Anticancer agent 258 is an imidazo [1,2-B][1,2,4] triazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors. Anticancer agent 258 has an EC50 of 63 nM against Nurr in N2A cells. Anticancer agent 258 has IC50 of 0.1 pM for Nur77in HEK293 cells. Anticancer agent 258 can be used in the study of cancer, metabolic diseases and neurological disorders[1]. |
| CAS | 2891984-12-4 |
| Formula | C17H12F2N4 |
| Molar Mass | 310.30 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Antonio ALMARIO, et al. Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy. US20240300956A1. 2024-09-12. |
Anticancer agent 258
CAS: 2891984-12-4 F: C17H12F2N4 W: 310.30
Anticancer agent 258 is an imidazotriazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.